Impact of statins on metastatic castration-resistant prostate cancer patients receiving new hormonal agents
Our study suggests a prognostic impact of statin use in the PFS in patients receiving abiraterone or enzalutamide for mCRPC. This may be related to the enhancement of the antitumor activity of the ADT drugs, but also to the cardioprotective effects associated with statin use.
Authors
- Roberto Jarimba (ORCID: https://orcid.org/0000-0001-5012-5141)
- Ana Marta Ferreira (ORCID: https://orcid.org/0000-0003-2079-8518)
- Arnaldo Figueiredo (ORCID: https://orcid.org/0000-0002-7157-0081)
- Vasco Quaresma (ORCID: https://orcid.org/0000-0001-9225-1437)
- Tiago Sousa (ORCID: https://orcid.org/0000-0002-3704-562X)
- Edgar Tavares-da-Silva (ORCID: https://orcid.org/0000-0002-8612-0147)
- P. Nunes
Institutions
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
Publication Details
- Journal
- Archivio Italiano di Urologia e Andrologia
- Published
- 2025-11-03
- DOI
- https://doi.org/10.4081/aiua.2025.14179
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00